Article ; Online: Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in healthcare workers at a designated COVID-19 hospital: a pilot study.
BMC infectious diseases
2021 Volume 21, Issue 1, Page(s) 536
Abstract: ... positivity in 99 healthcare workers (HCWs) at a hospital designated for treating COVID-19 patients ... of preexposure prophylaxis (PrEP) with aerosolized combination medication (ACM) on the incidence of SARS-CoV-2 ... within 28 days of the study period.: Results: SARS-CoV-2 was detected in 2 ACM users (2, 95% CI: 0.3 to 7 ...
| Abstract | Background: At present, no agents are known to be effective at preventing COVID-19. Based on current knowledge of the pathogenesis of this disease, we suggest that SARS-CoV-2 infection might be attenuated by directly maintaining innate pulmonary redox, metabolic and dilation functions using well-tolerated medications that are known to serve these functions, specifically, a low-dose aerosolized combination of glutathione, inosine and potassium. Methods: From June 1 to July 10, 2020, we conducted a pilot, prospective, open-label, single-arm, single-center study to evaluate the safety and efficacy of preexposure prophylaxis (PrEP) with aerosolized combination medication (ACM) on the incidence of SARS-CoV-2 positivity in 99 healthcare workers (HCWs) at a hospital designated for treating COVID-19 patients. We compared SARS-CoV-2 positivity in ACM users to retrospective data collected from 268 untreated HCWs at the same hospital. Eligible participants received an aerosolized combination of 21.3 mg/ml glutathione and 8.7 mg/ml inosine in 107 mM potassium solution for 14 days. The main outcome was the frequency of laboratory-confirmed SARS-CoV-2 cases, defined as individuals with positive genetic or immunological tests within 28 days of the study period. Results: SARS-CoV-2 was detected in 2 ACM users (2, 95% CI: 0.3 to 7.1%), which was significantly less than the incidence in nonusers, at 24 (9, 95% CI: 5.8 to 13.0%; P = 0.02). During the PrEP period, solicited adverse events occurred in five participants; all were mild and transient reactions. Conclusions: Our findings might be used either to prevent SARS-CoV-2 infection or to support ongoing and new research into more effective treatments for COVID-19. Trial registration: ISRCTN, ISRCTN34160010 . Registered 14 September 2020 - Retrospectively registered. |
|---|---|
| MeSH term(s) | Adult ; Aerosols/pharmacology ; COVID-19/drug therapy ; COVID-19/prevention & control ; Female ; Health Personnel ; Hospitals ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Pilot Projects ; Pre-Exposure Prophylaxis ; Prospective Studies ; Retrospective Studies ; Treatment Outcome |
| Chemical Substances | Aerosols |
| Language | English |
| Publishing date | 2021-06-07 |
| Publishing country | England |
| Document type | Journal Article |
| ISSN | 1471-2334 |
| ISSN (online) | 1471-2334 |
| DOI | 10.1186/s12879-021-06241-1 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.